A Single Centre Experience of Clinically Suspected Myelodysplastic Syndrome Cohort

Purpose: 1. To study clinical, histo-morphological and cytogenetic profile of clinically suspected MDS cases. 2. Categorisation according to recent WHO classification, IPSS-R scoring and clinical outcome.

Methods: This was a retrospective study conducted over a period of 2 years from Jan 2019 to Dec 2020. Laboratory received blood, bone marrow aspirate and biopsy samples with clinical diagnosis of MDS was reviewed in correlation with outsourced cytogenetic study reports in Haematology laboratory services department, Apollo Hospitals Bannerghatta road, Bengaluru.

Results: Based on WHO criteria, out of 50 cases, eight cases belonged to category ICOUS, and 7 cases fell into others. Out of the 35 cases, MDS EB-2 was noted in 23% of the cases. 25 cases were sent for cytogenetic study and 7 were positive. One case was positive for Monosomy 7, 2 for Trisomy 8, 4 for 5q deletion, and one of it had 5q deletion with trisomy 8. Packed red blood cells (PRBC) was transfused in 11 patients. Decitabine was the commonest hypomethylating agent given in 10 patients followed by lenalidomide in 5 patients. Out of 11 MDS EB-1 and MDS EB-2 cases, four patient died and both categories showed statistically significant risk of association between disease and poor outcome.

Conclusion: MDS EB-1 and EB-2 was the second commonest WHO category collaterally having the highest IPSS-R score and worst prognosis. 5q deletion was the commonest cytogenetic abnormality seen.